Brief: Scilex C.L.E.A.R. Program Trial Has Met Primary Efficacy And Key Secondary Efficacy Endpoints With Highly Statistical Significance
09/12/2021 14:03
Dec 9 (Reuters) - Vickers Vantage Corp I VCKA.O :
* SCILEX HOLDING COMPANY, A SORRENTO THERAPEUTICS, INC.
SUBSIDIARY, ANNOUNCES HIGHLY SIGNIFICANT POSITIVE TOP-LINE
RESULTS FROM ITS PHASE 3 NON-OPIOID INJECTABLE SP-102 (SEMDEXA™)
PIVOTAL TRIAL C.L.E.A.R. PROGRAM FOR SCIATICA PAIN MANAGEMENT
SUPPORTING THE POTENTIAL USE OF SP-102 AS A BEST-IN-CLASS
THERAPY
* SCILEX - C.L.E.A.R. PROGRAM TRIAL HAS MET PRIMARY EFFICACY
AND
KEY SECONDARY EFFICACY ENDPOINTS WITH HIGHLY STATISTICAL
SIGNIFICANCE
Source text for Eikon: ID:nGNXTHBhq
Further company coverage: VCKA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20